Key Takeaways
- Moderna (MRNA) has initiated global regulatory submissions for its investigational seasonal influenza vaccine, mRNA-1010, with major health authorities including the U.S. FDA, European Medicines Agency (EMA), Health Canada, and Australia's TGA.
- The mRNA-1010 vaccine demonstrated a robust relative vaccine efficacy (rVE) of 26.6% in adults aged 50 and older, and 27.4% in those 65 and older, against influenza illness in pivotal Phase 3 studies.
- British Prime Minister Keir Starmer unequivocally stated that the future of Greenland is a decision solely for Greenland and Denmark, directly countering recent remarks by U.S. President Donald Trump regarding potential acquisition.
Moderna Advances Seasonal Flu Vaccine with Global Filings
Moderna (MRNA) announced on Monday that it has commenced global regulatory submissions for its investigational seasonal influenza vaccine, mRNA-1010. The biotechnology firm has filed for marketing authorization with key regulatory bodies including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, and the Therapeutic Goods Administration (TGA) in Australia. These submissions target the use of mRNA-1010 in adults aged 50 years and older.
The regulatory applications are supported by positive data from multiple Phase 3 studies. In a pivotal efficacy study (P304), mRNA-1010 achieved a significant relative vaccine efficacy (rVE) of 26.6% (95% CI; 16.7%, 35.4%) across all adults aged 50 years and older. For participants aged 65 years and older, the vaccine showed an even stronger rVE of 27.4%.
Moderna's CEO, Stéphane Bancel, emphasized that the agility and flexibility of mRNA technology offer the potential to more closely match evolving influenza strains, thereby enhancing the response to one of the world's most persistent respiratory threats. If approved, mRNA-1010 could mark the introduction of the first mRNA-based influenza vaccine in the U.S. The company sees this as a crucial step for its respiratory portfolio and a significant opportunity to support continued growth for Moderna in 2027 and beyond. This development also opens avenues for potential combination vaccines, though Moderna recently withdrew a Biologics License Application (BLA) for its flu/COVID combination vaccine candidate (mRNA-1083) in consultation with the FDA.
Starmer Reaffirms Greenland's Self-Determination Amid Trump's Remarks
In a separate development, British Prime Minister Keir Starmer on Monday firmly asserted that the future of Greenland is a matter to be decided solely by Greenland and the Kingdom of Denmark. Starmer's comments were made in direct response to recent remarks by U.S. President Donald Trump, who reportedly expressed renewed interest in acquiring the vast Arctic territory.
Speaking to Sky News, Starmer stated, "Let me be really clear about Greenland, the future for Greenland is for Greenland [and] the Kingdom of Denmark." He expressed solidarity with Danish Prime Minister Mette Frederiksen, who had previously urged Trump to cease threatening Greenland. This intervention underscores the UK's support for the sovereignty of Greenland and Denmark, reiterating a stance against external pressures regarding the territory's status. President Trump had previously attempted to purchase Greenland during his first term, an offer that was rejected by Denmark and Greenland's government, who declared the island "not for sale."
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.